• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Matinas Biopharma Holdings Inc.

    8/14/25 4:06:47 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTNB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Matinas BioPharma Holdings, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    576810303

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    576810303


    1Names of Reporting Persons

    Highbridge Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    466,667.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    466,667.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    466,667.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The 466,667 shares of Common Stock (as defined in Item 2(a)) are issuable upon exercise of warrants reported herein.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Matinas BioPharma Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    1545 Route 206 South, Suite 302, Bedminster, NJ, 07921
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Matinas BioPharma Holdings, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.
    (c)Citizenship:

    Highbridge is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    576810303
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,086,985 shares of Common Stock outstanding as of May 15, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 15, 2025, and assumes the exercise of the warrants held by the Highbridge Funds.
    (b)Percent of class:

    8.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares of Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Highbridge Capital Management, LLC
     
    Signature:/s/ Kirk Rule
    Name/Title:Kirk Rule, Executive Director
    Date:08/14/2025
    Get the next $MTNB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTNB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTNB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

    BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

    3/11/25 7:00:00 AM ET
    $GRCE
    $MTNB
    $ONVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

    BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of

    2/13/25 5:00:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

    BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn

    2/7/25 7:30:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Matinas BioPharma downgraded by Piper Sandler

    Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral

    5/11/21 8:00:37 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Murphy Keith

    4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

    5/2/25 5:19:45 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Neugeboren Edward

    4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

    5/2/25 5:19:50 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Smith Robin L

    4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

    5/2/25 5:19:48 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    SEC Filings

    View All

    Matinas Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    8/18/25 6:30:39 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Matinas Biopharma Holdings Inc.

    10-Q - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    8/14/25 4:07:33 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Matinas Biopharma Holdings Inc.

    SCHEDULE 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    8/14/25 4:06:47 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Financials

    Live finance-specific insights

    View All

    Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

    BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available o

    8/7/24 7:00:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

    BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on the IR Ca

    5/2/24 7:00:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

    Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today

    3/27/24 4:05:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Leadership Updates

    Live Leadership Updates

    View All

    Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

    BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

    3/11/25 7:00:00 AM ET
    $GRCE
    $MTNB
    $ONVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

    BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of

    2/13/25 5:00:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

    BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn

    2/7/25 7:30:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Matinas Biopharma Holdings Inc.

    SC 13G - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    10/25/24 9:15:12 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Matinas Biopharma Holdings Inc. (Amendment)

    SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    2/14/22 4:43:03 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    2/16/21 5:01:52 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care